Paper23089736
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.
Sheehy SH and 31 others. Mol Ther, 2012. Cited by 176 papers, by iCite.
Cite this record
ConductScience Library. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Papers, record 23089736. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23089736
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antigens, Protozoan | Major topic |
| Culicidae | Major topic |
| Malaria Vaccines | Major topic |
| Merozoite Surface Protein 1 | Major topic |
| Adenoviruses, Simian | |
| Animals | |
| Flow Cytometry | |
| Humans | |
| Malaria, Falciparum | |
| Orthopoxvirus | |
| Pan troglodytes |
Source PubMed
Grants10
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| G0700735(82115) | Medical Research Council | United Kingdom | PubMed | PubMed | |
| G1000527 | Medical Research Council | United Kingdom | PubMed | PubMed | |
| 094449/Z/10/Z | Wellcome Trust | United Kingdom | PubMed | PubMed | |
| 095540 | Wellcome Trust | United Kingdom | PubMed | PubMed | |
| 090532 | Wellcome Trust | United Kingdom | PubMed | PubMed | |
| 084113/Z/07/Z | Wellcome Trust | United Kingdom | PubMed | PubMed | |
| 45488/Z/05 | Wellcome Trust | United Kingdom | PubMed | PubMed | |
| G1000527(95710) | Medical Research Council | United Kingdom | PubMed | PubMed | |
| G0700735 | Medical Research Council | United Kingdom | PubMed | PubMed | |
| ZIAAI001020 | NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02485912 | Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination | Background |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 23201615 | Still seeking an effective "one-two" malaria vaccine punch. | https://conductscience.org/library/papers/23201615 |
Source PubMed
References50
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19857448 | Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. | Vaccine | 2009 | https://conductscience.org/library/papers/19857448 | PubMed |
| 2 | 1625908 | Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. | Parasite Immunol | 1992 | https://conductscience.org/library/papers/1625908 | PubMed |
| 3 | 19627632 | The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. | Parasitology | 2009 | https://conductscience.org/library/papers/19627632 | PubMed |
| 4 | 10861076 | CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization. | J Immunol | 2000 | https://conductscience.org/library/papers/10861076 | PubMed |
| 5 | 10462251 | Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. | Vaccine | 1999 | https://conductscience.org/library/papers/10462251 | PubMed |
| 6 | 2258697 | Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. | J Exp Med | 1990 | https://conductscience.org/library/papers/2258697 | PubMed |
| 7 | 21876036 | Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference. | J Immunol | 2011 | https://conductscience.org/library/papers/21876036 | PubMed |
| 8 | 22186897 | The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. | Nat Commun | 2011 | https://conductscience.org/library/papers/22186897 | PubMed |
| 9 | 17015763 | Innate immune responses to human malaria: heterogeneous cytokine responses to blood-stage Plasmodium falciparum correlate with parasitological and clinical outcomes. | J Immunol | 2006 | https://conductscience.org/library/papers/17015763 | PubMed |
| 10 | 22363582 | Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. | PLoS One | 2012 | https://conductscience.org/library/papers/22363582 | PubMed |
| 11 | 22275401 | Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. | J Infect Dis | 2012 | https://conductscience.org/library/papers/22275401 | PubMed |
| 12 | 15655787 | Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. | J Infect Dis | 2005 | https://conductscience.org/library/papers/15655787 | PubMed |
| 13 | 11738714 | Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. | Mol Biochem Parasitol | 2001 | https://conductscience.org/library/papers/11738714 | PubMed |
| 14 | 22492136 | Controlled human blood stage malaria infection: current status and potential applications. | Am J Trop Med Hyg | 2012 | https://conductscience.org/library/papers/22492136 | PubMed |
| 15 | 18660818 | Effective induction of high-titer antibodies by viral vector vaccines. | Nat Med | 2008 | https://conductscience.org/library/papers/18660818 | PubMed |
| 16 | 16014857 | Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. | Am J Trop Med Hyg | 2005 | https://conductscience.org/library/papers/16014857 | PubMed |
| 17 | 22218690 | Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. | Sci Transl Med | 2012 | https://conductscience.org/library/papers/22218690 | PubMed |
| 18 | 19154991 | Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria. | Cell Host Microbe | 2009 | https://conductscience.org/library/papers/19154991 | PubMed |
| 19 | 15306710 | Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. | Am J Trop Med Hyg | 2004 | https://conductscience.org/library/papers/15306710 | PubMed |
| 20 | 12241933 | Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. | Lancet | 2002 | https://conductscience.org/library/papers/12241933 | PubMed |
Cited by144
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 176 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42504823 | An abundant merozoite surface protein of Plasmodium falciparum modulates susceptibility to inhibitory antibodies. | Elife | 2026 | https://conductscience.org/library/papers/42504823 | PubMed |
| 42497177 | Broad and durable protection against SARS-CoV-2 and SARS-CoV by an intranasal chimpanzee adenovirus vaccine expressing tandem RBDs and nucleocapsid. | PLoS Pathog | 2026 | https://conductscience.org/library/papers/42497177 | PubMed |
| 42159668 | Adenoviral Vectors in Gene Therapy: A Detailed Overview. | Iran Biomed J | 2026 | https://conductscience.org/library/papers/42159668 | PubMed |
| 41970240 | Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults. | Wellcome Open Res | 2024 | https://conductscience.org/library/papers/41970240 | PubMed |
| 41545594 | Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial. | Nat Med | 2026 | https://conductscience.org/library/papers/41545594 | PubMed |
| 41405971 | Harnessing controlled human infection models to accelerate vaccine development for neglected tropical diseases: Lessons from leishmaniasis. | Eur J Clin Invest | 2026 | https://conductscience.org/library/papers/41405971 | PubMed |
| 41050675 | Controlled human malaria infection studies: insights into recent advances and key immunological and ethical implementation lessons. | Front Immunol | 2025 | https://conductscience.org/library/papers/41050675 | PubMed |
| 40563989 | Malaria Vaccines and Global Equity: A Scoping Review of Current Progress and Future Directions. | Biomedicines | 2025 | https://conductscience.org/library/papers/40563989 | PubMed |
| 39893367 | Controlled human malaria infection: overview and potential application in the evaluation of transmission-blocking interventions in malaria-endemic areas. | Malar J | 2025 | https://conductscience.org/library/papers/39893367 | PubMed |
| 39628785 | Role of homologous recombination/recombineering on human adenovirus genome engineering: Not the only but the most competent solution. | Eng Microbiol | 2024 | https://conductscience.org/library/papers/39628785 | PubMed |
| 38803222 | Full-length MSP1 is a major target of protective immunity after controlled human malaria infection. | Life Sci Alliance | 2024 | https://conductscience.org/library/papers/38803222 | PubMed |
| 38506710 | Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses. | Clin Cancer Res | 2024 | https://conductscience.org/library/papers/38506710 | PubMed |
| 38184681 | PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial. | NPJ Vaccines | 2024 | https://conductscience.org/library/papers/38184681 | PubMed |
| 38098083 | A dual-antigen malaria vaccine targeting Pb22 and Pbg37 was able to induce robust transmission-blocking activity. | Parasit Vectors | 2023 | https://conductscience.org/library/papers/38098083 | PubMed |
| 37626150 | Immunogenicity of a Plasmodium vivax vaccine based on the duffy binding protein formulated using adjuvants compatible for use in humans. | Sci Rep | 2023 | https://conductscience.org/library/papers/37626150 | PubMed |
| 37558673 | Multifunctional IgG/IgM antibodies and cellular cytotoxicity are elicited by the full-length MSP1 SumayaVac-1 malaria vaccine. | NPJ Vaccines | 2023 | https://conductscience.org/library/papers/37558673 | PubMed |
| 37515003 | Adenovirus Transcriptome in Human Cells Infected with ChAdOx1-Vectored Candidate HIV-1 Vaccine Is Dominated by High Levels of Correctly Spliced HIVconsv1&62 Transgene RNA. | Vaccines (Basel) | 2023 | https://conductscience.org/library/papers/37515003 | PubMed |
| 37310872 | The Dantu blood group prevents parasite growth in vivo: Evidence from a controlled human malaria infection study. | Elife | 2023 | https://conductscience.org/library/papers/37310872 | PubMed |
| 36985500 | Natural Plasmodium falciparum Infection Stimulates Human Antibodies to MSP1 Epitopes Identified in Mice Infection Models upon Non-Natural Modified Peptidomimetic Vaccination. | Molecules | 2023 | https://conductscience.org/library/papers/36985500 | PubMed |
| 36365010 | Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs. | Pathogens | 2022 | https://conductscience.org/library/papers/36365010 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23089736
GET https://conductscience.org/api/papers/v1/23089736/authors?page=2